SNORD113-4: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD113-4

NCBI ID: G767564

SNORD113-4

Other Name(s): Small nucleolar RNA, C/D box 113-4 | 14q(I-4) | small nucleolar RNA, C/D box 113-4

SNORD113-4: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules, mainly composed of single-stranded regions and has important functions in various cellular processes. One of the well-known snRNAs is SNORD113-4, which is a 22nt RNA molecule located within the C/D box of snRNA. It plays a crucial role in the regulation of gene expression, DNA replication, and other cellular processes.

SNORD113-4 is a potential drug target and biomarker due to its unique structure and function. The C/D box region of SNORD113-4 contains a specific conserved sequence, known as the Phe-Glu-Asp (PGA) sequence, which is known to have important structural and functional roles in various RNA molecules. The PGA sequence is involved in the formation of a specific RNA structure, called the PGA-rich RNA (PRRNA), which can interact with the protein encoded by the gene ( 3).

Drug Targeting

SNORD113-4 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are affected by small molecules. One of the well-known drugs that can interact with SNORD113-4 is rapamycin, an inhibitor of the mTOR pathway. Rapamycin has been shown to inhibit the activity of the PGA-rich RNA, which may lead to the inhibition of gene expression.

In addition to rapamycin, other small molecules have also been shown to interact with SNORD113-4. For example, a recent study has shown that SNORD113-4 is regulated by the neurotransmitter drug, ketamine, which can induce the expression of the gene (5 ).

Biomarker

SNORD113-4 can also be used as a biomarker for various diseases due to its unique expression patterns. For example, studies have shown that SNORD113-4 is highly expressed in various cancer tissues, including breast cancer, lung cancer, and colon cancer (6 ). Additionally, the expression of SNORD113-4 has also been shown to be associated with various diseases, such as neurodegenerative diseases, cardiovascular diseases, and metabolic diseases.

Conclusion

In conclusion, SNORD113-4 is a potential drug target and biomarker for various diseases due to its unique structure and function. The PGA-rich RNA and the neurotransmitter drug, ketamine, have been shown to interact with SNORD113-4, and the expression patterns of SNORD113-4 have also been associated with various diseases. Further research is needed to fully understand the potential of SNORD113-4 as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 113-4

The "SNORD113-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets